About
VeinWay is focused on developing a novel technology for crossing chronically occluded veins.
VeinWay's Traversa delivers the first dedicated device designed for venous recanalization that will improve outcomes and allow physicians to reliably, safely and easily complete endovascular procedures in a timely manner for the effective treatment of CVOs. The Traversa is an enabling technology which will disrupt the market by democratizing physician access to the treatment of CVOs. The innovation has a significantly different approach compared to existing solutions on the market or that are currently in development. All other solutions are either off-label tools that have a high risk of perforation, or standard crossing tools with no specific indication or features for venous recanalization. Physicians use them as workarounds when the procedure fails with standard guidewires. In contrast, Traversa is the first tool designed specifically for crossing CVOs, allowing for an unparalleled level of control that will enable interventional radiologists and vascular surgeons to cross occlusions every time.
VeinWay was created as part of the entrepreneur in residence program with the MEDX Xelerator, which supports and helps inventors and entrepreneurs cultivate early-stage ideas addressing complex unmet clinical needs.
Funding history · 2 rounds · $7.4M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is VeinWay's primary focus?
- VeinWay is focused on developing novel technology for crossing chronically occluded veins, specifically with its Traversa device.
- When was VeinWay founded?
- VeinWay was founded in November 2020.
- How many employees does VeinWay currently have?
- VeinWay currently has 6 employees.
- What is the total amount of funding VeinWay has raised?
- VeinWay has raised a total of $7,435,000 USD.
- Which investors participated in VeinWay's Seed round in September 2023?
- In September 2023, VeinWay closed a Seed round with participation from Consensus Business Group (CBG) and Boston Scientific.
- When did VeinWay secure its Series A funding round?
- VeinWay secured its Series A funding round in November 2023, raising $5,000,000 USD.
- What grants has VeinWay received from the IIA?
- VeinWay received a grant of $35,000 USD from the IIA in December 2020 and another grant of $800,000 USD in May 2021.
- What is the current product stage of VeinWay's Traversa device?
- VeinWay's Traversa device is currently in the clinical trial stage.
- Where is VeinWay's headquarters located?
- VeinWay's headquarters is located in Or Yehuda, Center District, Israel.